Elyn Riedel, MA

Senior Research Biostatistician Manager, Consulting Service

Elyn Riedel, MA

Senior Research Biostatistician Manager, Consulting Service

Office Phone

646-888-8292

E-mail

riedele@mskcc.org

Current Research Interests

Ms. Riedel currently manages the Department’s Consulting Service. Through the service, she collaborates with a variety of investigators from Memorial Hospital and SKI.

Ms. Riedel co-chairs Biostatistics Protocol Review and Analysis Workshop.  She also serves as Randomization Coordinator of the Biostatistics Service and is responsible for the design and maintenance of the treatment allocation schema for the Center’s randomized protocols.

Publications

Selected Bibliography


  1. Begg, C.B., E.R. Riedel, P.B. Bach, M.W. Kattan, D. Schrag, J.L. Warren, and P.T. Scardino, Variations in morbidity after radical prostatectomy. N Engl J Med, 2002. 346(15): p. 1138-44.

  2. Shike, M., L. Latkany, E. Riedel, M. Fleisher, A. Schatzkin, E. Lanza, D. Corle, and C.B. Begg, Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. J Clin Oncol, 2002. 20(17): p. 3592-8.

  3. Panageas, K.S., D. Schrag, E. Riedel, P.B. Bach, and C.B. Begg, The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med, 2003. 139(8): p. 658-65.

  4. Hormigo, A., B. Gu, S. Karimi, E. Riedel, K.S. Panageas, M.A. Edgar, M.K. Tanwar, J.S. Rao, M. Fleisher, L.M. DeAngelis, and E.C. Holland, YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res, 2006. 12(19): p. 5698-704.

  5. Goodman, K.A., E. Riedel, V. Serrano, S. Gulati, C.H. Moskowitz, and J. Yahalom, Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol, 2008. 26(32): p. 5240-7.

  6. Iasonos, A., A.S. Wilton, E.R. Riedel, V.E. Seshan, and D.R. Spriggs, A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials, 2008. 5(5): p. 465-77.

Read more
  1. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, RIEDEL E, Yao TJ, Norton L: Sequential high dose adjuvant doxorubicin, paclitaxel, and cyclophosphamide with G-CSF is feasible for women with resected breast cancer and > 4 (+) lymph nodes. Proceedings of ASCO. 1994. 13: 65.
  2. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, RIEDEL E, Yao TJ, Norton L: Sequential high-dose adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide for resectable breast cancer involving four or more axillary. Satellite Symposium, ESMO. November 1994.
  3. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, RIEDEL E, Yao TJ, Norton L: Sequential doxorubicin, paclitaxel, and cyclophosphamide in women with resected breast cancer and > = 4(+) lymph nodes: Preliminary results. Proceedings of ASCO 1995. 14: 152.
  4. Minasian L, Yao TJ, Steffens T, Scheinberg D, Williams L, RIEDEL E, Houghton A, Chapman P: A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophase-colony stimulating factor in patients with metastatic melanoma. Cancer 1995. 75: 2251-2257.
  5. Barendswaard E, Scott A, Divgi C, Williams C, Coplan K, RIEDEL E, Yao TJ, Gansow O, Finn R, Larson S, Old L, Welt S: Rapid and Specific Targeting of Monoclonal Antibody A33 to a Colon Cancer Xenograft in Nude Mice. International Journal of Oncology 1998. 12: 45-53.
  6. Hudis C, Seidman A, Baselga J, Patis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, RIEDEL E, Yao TJ, Norton L: Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high risk breast cancer: feasibility and efficacy. Journal of Clinical Oncology 1999. 17: 93-100.
  7. Fishman J, Reynolds T, RIEDEL E: A retrospective investigation of an intensive outpatients substance abuse treatment program. The American Journal of Drug and Alcohol Abuse. 1999. 25: 185-196.
  8. Yeung HWD, Cody HS, Turlakow A, RIEDEL ER, Fey J, Gonen M, Nunez R, Yeh SD, Larson SM. LSG and SNL at surgery in breast cancer patients: Comparison between one-day and two-day protocols. Journal of Nuclear Medicine 2001. 42: 420-423.
  9. Ramos CD, Erdi YE, Gonen M, RIEDEL E, Yeung HW, Macapinlac HA, Chisin R, Larson SM: FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. European Journal of Nuclear Medicine 2001. 28: 155-164.
  10. Olson JD, RIEDEL E, DeAngelis LM: Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000. 54: 1442-1448.
  11. Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, RIEDEL E, Scher HI, Larson SM: 18F-FDG and 11C methionine PET scans in patients with newly progressive metastatic prostate cancer. Journal of Nuclear Medicine 2002. 43: 46-55.
  12. Begg CB, RIEDEL ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT: Variations in morbidity following radical prostatectomy. New England Journal of Medicine 2001. 346: 1138-1144.
  13. Potosky AL, Warren JL, RIEDEL ER, Klabunde CN, Earle CC, Begg CB: Measuring complications of cancer treatment using the SEER-Medicare data. Medical Care 2002. (in press).
  14. Schrag D, Panageas KS, RIEDEL E, Cramer LD, Guillem JG, Bach PB, Begg CB: Surgeon volume compared to hospital volume as a predictor of outcome following rectal cancer surgery. Annals of Surgery 2002. 5;583-592.

My Pages